← Back to headlines
Truist Raises Its Price Target on BridgeBio Pharma, Inc. (BBIO) to $95 and Maintains a Buy Rating
Truist has raised its price target for BridgeBio Pharma, Inc. (BBIO) to $95, reiterating a Buy rating for the pharmaceutical company.
6 Mar, 15:20 — 6 Mar, 15:20
Sources
Showing 1 of 1 sources
Related Stories
US Army Awards $2.2 Billion for Nuclear Microreactors at Five Bases
16m ago
Oil Prices Decline on Prospects of Diplomatic Talks to Ease Middle East Supply Disruptions
37m ago
FSSAI Issues Food Safety Notices to Premier Delhi Hotels Ahead of BRICS Summit
54m ago
South Korea Central Bank Raises Rates to 3%, Upgrades Growth Forecast
54m ago